Equity Profile

APLS

Apellis Pharmaceuticals, Inc.

Health CareBiotechnology$5.3B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Apellis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and generate sales from its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

APLS Q2-2026 Earnings Preview

Context

Company Snapshot

Apellis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases. Operating in the health care sector, its work is particularly relevant as the demand for advanced medical treatments continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+40.64%

Avg Stock Reaction

-4.40%

Last Quarter Recap

In Q1-2026, Apellis reported an EPS of $0.15, significantly beating expectations. However, the stock experienced a slight decline the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as Apellis has shown strong EPS surprises in recent quarters, but the stock has not consistently reacted positively.

Bull Case

If Apellis continues its trend of beating EPS estimates, it could signal strong operational performance and growth potential, leading to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, especially given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's recent performance, the EPS figure will be crucial in determining market sentiment and stock movement.

What guidance will management provide for future quarters?

Management's outlook on revenue and growth will be key for investors assessing the company's long-term potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Apellis to exceed EPS expectations due to its recent operational improvements and product pipeline.

Supporting Evidence

The company has consistently surprised on EPS in recent quarters, indicating strong underlying performance.

Options pricing suggests a significant move, which may reflect greater confidence in the company's growth prospects than what consensus indicates.

Key Risk

If the EPS comes in above $0.20, it could challenge the current bearish sentiment and shift investor perception.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will either reinforce the company's growth narrative or highlight potential weaknesses.

Bull Confirmed If

A positive EPS of $0.20 or higher would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $0.10 would confirm the bear case and raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±34.35%

Historical Avg

±8.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect considerable volatility around the earnings announcement.

Options are pricing ±34.3% while APLS has averaged ±8.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

2.6%

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Apellis beats expectations, history suggests the stock could rise by an average of 4.6%, confirming a bullish outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline in stock price, with historical patterns indicating an average drop of 3.8%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements and their expected impact on revenue.
2Management's commentary on market conditions and competitive landscape.
3Details on cost management strategies and their effect on profitability.
4Insights into customer acquisition and retention metrics.
5Guidance on future earnings and revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Apellis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and generate sales from its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

APLS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+40.64%

Avg Stock Reaction

-4.40%

Last Quarter Recap

In Q1-2026, Apellis reported an EPS of $0.15, significantly beating expectations. However, the stock experienced a slight decline the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as Apellis has shown strong EPS surprises in recent quarters, but the stock has not consistently reacted positively.

Bull Case

If Apellis continues its trend of beating EPS estimates, it could signal strong operational performance and growth potential, leading to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, especially given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's recent performance, the EPS figure will be crucial in determining market sentiment and stock movement.

What guidance will management provide for future quarters?

Management's outlook on revenue and growth will be key for investors assessing the company's long-term potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Apellis to exceed EPS expectations due to its recent operational improvements and product pipeline.

Supporting Evidence

The company has consistently surprised on EPS in recent quarters, indicating strong underlying performance.

Options pricing suggests a significant move, which may reflect greater confidence in the company's growth prospects than what consensus indicates.

Key Risk

If the EPS comes in above $0.20, it could challenge the current bearish sentiment and shift investor perception.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will either reinforce the company's growth narrative or highlight potential weaknesses.

Bull Confirmed If

A positive EPS of $0.20 or higher would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $0.10 would confirm the bear case and raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±34.35%

Historical Avg

±8.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect considerable volatility around the earnings announcement.

Options are pricing ±34.3% while APLS has averaged ±8.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

2.6%

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Apellis beats expectations, history suggests the stock could rise by an average of 4.6%, confirming a bullish outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline in stock price, with historical patterns indicating an average drop of 3.8%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements and their expected impact on revenue.
2Management's commentary on market conditions and competitive landscape.
3Details on cost management strategies and their effect on profitability.
4Insights into customer acquisition and retention metrics.
5Guidance on future earnings and revenue expectations.